FGFR1 and myeloid neoplasm: Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, given at an oral dose of 20 mg once daily, has been assessed in a 55-year-old male, resulting in the first reported case of complete hematologic and cytogenetic remission in an FGFR1-driven myeloid neoplasm [49].